ARTICLE | Clinical News
Flibanserin regulatory update
February 23, 2015 8:00 AM UTC
Sprout resubmitted an NDA to FDA for flibanserin to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. The submission includes results from a Phase I pharmacokinetics trial and a P...